Peroxisome proliferator-activated receptor γ and colorectal cancer
Authors:
Open Access
- 1 January 2010
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 2 (3) , 159-64
Abstract
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily and ligand-activated transcription factors. PPARγ plays an important role in adipocyte differentiation, lipid storage and energy dissipation in adipose tissue, and is involved in the control of inflammatory reactions as well as in glucose metabolism through the improvement of insulin sensitivity. Growing evidence has demonstrated that activation of PPARγ has an antineoplastic effect in tumors, including colorectal cancer. High expression of PPARγ is detected in human colon cancer cell lines and adenocarcinoma. This review describes the molecular mechanisms by which PPARγ regulates tumorigenesis in colorectal cancer, and examines current clinical trials evaluating PPARγ agonists as therapeutic agents for colorectal cancer.Keywords
This publication has 77 references indexed in Scilit:
- Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance.2008
- Synergistic Effects of PPARγ Ligands and Retinoids in Cancer TreatmentPPAR Research, 2008
- Peroxisome Proliferator-activated Receptor γ Activation Can Regulate β-Catenin Levels via a Proteasome-mediated and Adenomatous Polyposis Coli-independent PathwayJournal of Biological Chemistry, 2004
- Frequent polymorphism of peroxisome proliferator activated receptor γ gene in colorectal cancer containing wild-type K-ras geneInternational Journal of Molecular Medicine, 2002
- Activation of peroxisome proliferator-activated receptor-γ stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cellsOncogene, 2002
- The PPARs: From Orphan Receptors to Drug DiscoveryJournal of Medicinal Chemistry, 2000
- Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*Endocrine Reviews, 1999
- Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcomaProceedings of the National Academy of Sciences, 1999
- Thiazolidinediones: a new class of antidiabetic drugsDiabetic Medicine, 1999
- Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawalJournal of Clinical Investigation, 1999